Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis
详细信息 查看全文
- 作者：Rajesh Ravindran (1) (2)
Sudipta Bhowmick (1) (3)
Amrita Das (1)
Nahid Ali (1) - 刊名：BMC Microbiology
- 出版年：2010
- 出版时间：December 2010
- 年：2010
- 卷：10
- 期：1
- 全文大小：1156KB
- 参考文献：1. Desjeux P: Leishmaniasis: current situation and new perspectives. / Comp Immunol Microbiol Infect Dis 2004, 27:305-18. CrossRef
2. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, Alvar J, Boelaert M: Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? / Nat Rev Microbiol 2007, 5:873-82. CrossRef
3. Bhowmick S, Ali N: Recent developments in leishmaniasis vaccine delivery systems. / Expert Opin Drug Deliv 2008, 5:789-03. CrossRef
4. Heldwein KA, Liang MD, Andresen TK, Thomas KE, Marty AM, Cuesta N, Vogel SN, Fenton MJ: TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCG. / J Leukoc Biol 2003, 74:277-86. CrossRef
5. von Meyenn F, Schaefer M, Weighardt H, Bauer S, Kirschning CJ, Wagner H, Sparwasser T: Toll-like receptor 9 contributes to recognition of Mycobacterium bovis Bacillus Calmette-Guerin by Flt3-ligand generated dendritic cells. / Immunobiology 2006, 211:557-65. CrossRef
6. Villarreal-Ramos B: Towards improved understanding of protective mechanisms induced by the BCG vaccine. / Expert Rev Vaccines 2009, 8:1531-534. CrossRef
7. Smrkovski LL, Larson CL: Effect of treatment with BCG on the course of visceral leishmaniasis in BALB/c mice. / Infect Immun 1977, 16:249-57.
8. Weintraub J, Weinbaum FI: The effect of BCG on experimental cutaneous leishmaniasis in mice. / J Immunol 1977, 118:2288-290.
9. Noazin S, Modabber F, Khamesipour A, Smith PG, Moulton LH, Nasseri K, Sharifi I, Khalil EA, Bernal ID, Antunes CM, Kieny MP, Tanner M: First generation leishmaniasis vaccines: a review of field efficacy trials. / Vaccine 2008, 26:6759-767. CrossRef
10. Reed SG, Bertholet S, Coler RN, Friede M: New horizons in adjuvants for vaccine development. / Trends Immunol 2009, 30:23-2. CrossRef
11. Chikh GG, Kong S, Bally MB, Meunier JC, Schutze Redelmeier MP: Efficient delivery of Antennapedia homeodomain fused to CTL epitope with liposomes into dendritic cells results in the activation of CD8 + T cells. / J Immunol 2001, 167:6462-470.
12. Nakanishi T, Kunisawa J, Hayashi A, Tsutsumi Y, Kubo K, Nakagawa S, Nakanishi M, Tanaka K, Mayumi T: Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble proteins. / J Control Release 1999, 61:233-40. CrossRef
13. Rao M, Alving CR: Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. / Adv Drug Deliv Rev 2000, 41:171-88. CrossRef
14. Mazumdar T, Anam K, Ali N: Influence of phospholipid composition on the adjuvanticity and protective efficacy of liposome-encapsulated Leishmania donovani antigens. / J Parasitol 2005, 91:269-74. CrossRef
15. Afrin F, Ali N: Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes. / Infect Immun 1997, 65:2371-377.
16. Bhowmick S, Ravindran R, Ali N: Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response. / Vaccine 2007, 25:6544-556. CrossRef
17. Bhowmick S, Ravindran R, Ali N: gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani . / Infect Immun 2008, 76:1003-015. CrossRef
18. Bhowmick S, Ali N: Identification of novel Leishmania donovani antigens that help define correlates of vaccine-mediated protection in visceral leishmaniasis. / PLoS One 2009, 4:e5820. CrossRef
19. McMahon-Pratt D, Alexander J: Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease? / Immunol Rev 2004, 201:206-24. CrossRef
20. Engwerda CR, Murphy ML, Cotterell Sara EJ, Smelt Sara C, Kaye PM: Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani . / Eur J Immunol 1998, 28:669-80. CrossRef
21. Kaye PM, Curry AJ, Blackwell JM: Differential production of Th1 and Th2-derived cytokines does not determine the genetically controlled or vaccine induced rate of cure in murine visceral leishmaniasis. / J Immunol 1991, 146:2763-770.
22. Melby PC, Yang J, Zhao W, Perez LE, Cheng J: Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. / Infect Immun 2001, 69:4719-725. CrossRef
23. Miralles GD, Stoeckle MY, McDermott DF, Finkelman FD, Murray HW: Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. / Infect Immun 1994, 62:1058-063.
24. Murray HW, Hariprashad J, Coffman RL: Behavior of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated response model. / J Exp Med 1997, 185:867-74. CrossRef
25. Satoskar A, Bluethmann H, Alexander J: Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. / Infect Immun 1995, 63:4894-899.
26. Alexander J, Carter KC, Al-Fasi N, Satoskar A, Brombacher F: Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. / Eur J Immunol 2000, 30:2935-943. CrossRef
27. Mazumdar T, Anam K, Ali N: A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice. / Vaccine 2004, 22:1162-171. CrossRef
28. Afrin F, Ali N: Isotype profiles of Leishmania donovani -infected BALB/c mice: preferential stimulation of IgG2a/b by liposome-associated promastigotes antigens. / J Parasitol 1998, 84:743-48. CrossRef
29. Bhowmick S, Mazumdar T, Sinha R, Ali N: Comparison of liposome based antigen delivery systems for protection against Leishmania donovani . / J Control Release 2010, 141:199-07. CrossRef
30. Jaafari MR, Badiee A, Khamesipour A, Samiei A, Soroush D, Kheiri MT, Barkhordari F, McMaster WR, Mahboudi F: The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome. / Vaccine 2007, 25:6107-117. CrossRef
31. Armijos RX, Weigel MM, Calvopina M, Hidalgo A, Cevallos W, Correa J: Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis. / Vaccine 2004, 22:1320-326. CrossRef
32. Khalil EA, El Hassan AM, Zijlstra EE, Mukhtar MM, Ghalib HW, Musa B, Ibrahim ME, Kamil AA, Elsheikh M, Babiker A, Modabber F: Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. / Lancet 2000, 356:1565-569. CrossRef
33. Tripathi P, Gupta SK, Sinha S, Sundar S, Dube A, Naik S: Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis. / Scand J Immunol 2008, 68:492-01. CrossRef
34. Kumari S, Samant M, Misra P, Khare P, Sisodia B, Shasany AK, Dube A: Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa offers long-lasting protection against experimental visceral leishmaniasis. / Vaccine 2008, 26:5700-711. CrossRef
35. Santos WR, de Lima VM, de Souza EP, Bernardo RR, Palatnik M, Palatnik de Sousa CB: Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. / Vaccine 2002, 21:30-3. CrossRef
36. Aebischer T, Wolfram M, Patzer SI, Ilg T, Wiese M, Overath P: Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants. / Infect Immun 2000, 68:1328-336. CrossRef
37. Coler RN, Goto Y, Bogatzki L, Raman V, Reed SG: Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4 + T cells. / Infect Immun 2007, 75:4648-654. CrossRef
38. Ghalib H, Modabber F: Consultation meeting on the development of therapeutic vaccines for post kala azar dermal leishmaniasis. / Kinetoplastid Biol Dis 2007, 6:7. CrossRef
39. Vélez ID, Gilchrist K, Martínez S, Ramírez-Pineda JR, Ashman JA, Alves FP, Coler RN, Bogatzki LY, Kahn SJ, Beckmann AM, Cowgill KD, Reed SG, Piazza FM: Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. / Vaccine 2009, 28:329-37. CrossRef
40. Goto Y, Bogatzki LY, Bertholet S, Coler RN, Reed SG: Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant. / Vaccine 2007, 25:7450-458. CrossRef
41. Nagill R, Kaur S: Enhanced efficacy and immunogenicity of 78 kDa antigen formulated in various adjuvants against murine visceral leishmaniasis. / Vaccine 2010, 28:4002-012. CrossRef
42. Bhardwaj S, Vasishta RK, Arora SK: Vaccination with a novel recombinant Leishmania antigen plus MPL provides partial protection against L. donovani challenge in experimental model of visceral leishmaniasis. / Exp Parasitol 2009, 121:29-7. CrossRef
43. Dietrich J, Billeskov R, Doherty TM, Andersen P: Synergistic effect of bacillus calmette guerin and a tuberculosis subunit vaccine in cationic liposomes: increased immunogenicity and protection. / J Immunol 2007, 178:3721-0.
44. Ghosh A, Zhang WW, Matlashewski G: Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. / Vaccine 2001, 20:59-6. CrossRef
45. Cui Y, Choi IS, Koh YA, Lin XH, Cho YB, Won YH: Effects of combined BCG and DHEA treatment in preventing the development of asthma. / Immunol Invest 2008, 37:191-02. CrossRef
46. Oscherwitz J, Hankenson FC, Yu F, Cease K: Low-dose intraperitoneal Freund's adjuvant: toxicity and immunogenicity in mice using an immunogen targeting amyloid-beta peptide. / Vaccine 2006, 24:3018-025. CrossRef
47. Bhowmick S, Mazumdar T, Ali N: Vaccination route that induces transforming growth factor beta production fails to elicit protective immunity against Leishmania donovani infection. / Infect Immun 2009, 77:1514-523. CrossRef
48. Wijburg OL, van den Dobbelsteen GP, Vadolas J, Sanders A, Strugnell RA, van Rooijen N: The role of macrophages in the induction and regulation of immunity elicited by exogenous antigens. / Eur J Immunol 1998, 28:479-87. CrossRef
49. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. / J Biol Chem 1951, 193:265-75.
50. Stewart JC: Colorimetric determination of phospholipids with ammonium ferrothiocyanate. / Anal Biochem 1980, 104:10-4. CrossRef
51. Stauber LA, Franchino EM, Grun J: An eight day method for screening compounds against Leishmania donovani in the golden hamster. / J Protozool 1958, 5:269-73. - 作者单位：Rajesh Ravindran (1) (2)
Sudipta Bhowmick (1) (3)
Amrita Das (1)
Nahid Ali (1)
1. Infectious Diseases and Immunology Division, Indian Institute of Chemical Biology, 4 Raja S. C. Mullick Road, 700032, Jadavpur, Kolkata, India
2. Department of Pathology, Emory Vaccine Center, 954 Gatewood Road, 30329, Atlanta, GA, USA
3. Department of Zoology, Dr. Kanailal Bhattacharyya College, Dharmatala, Ramrajatala, Santragachi, Howrah, 711104, India - ISSN：1471-2180
文摘
Background The development of an effective vaccine against visceral leishmaniasis (VL) caused by Leishmania donovani is an essential aim for controlling the disease. Use of the right adjuvant is of fundamental importance in vaccine formulations for generation of effective cell-mediated immune response. Earlier we reported the protective efficacy of cationic liposome-associated L. donovani promastigote antigens (LAg) against experimental VL. The aim of the present study was to compare the effectiveness of two very promising adjuvants, Bacille Calmette-Guerin (BCG) and Monophosphoryl lipid A (MPL) plus trehalose dicorynomycolate (TDM) with cationic liposomes, in combination with LAg, to confer protection against murine VL. Results All the three formulations afforded significant protection against L. donovani in both the visceral organs, liver and spleen. Although comparable level of protection was observed in BCG+LAg and MPL-TDM+LAg immunized mice, highest level of protection was exhibited by the liposomal LAg immunized group. Significant increase in anti-LAg IgG levels were detected in both MPL-TDM+LAg and liposomal LAg immunized animals with higher levels of IgG2a than IgG1. But BCG+LAg failed to induce any antibody response. As an index of cell-mediated immunity DTH responses were measured and significant response was observed in mice vaccinated with all the three different formulations. However, highest responses were observed with liposomal vaccine immunization. Comparative evaluation of IFN-γ and IL-4 responses in immunized mice revealed that MPL-TDM+LAg group produced the highest level of IFN-γ but lowest IL-4 level, while BCG+LAg demonstrated generation of suboptimum levels of both IFN-γ and IL-4 response. Elicitation of moderate levels of prechallenge IFN-γ along with optimum IL-4 corresponds with successful vaccination with liposomal LAg. Conclusion This comparative study reveals greater effectiveness of the liposomal vaccine for protection against progressive VL in BALB/c. Again, evaluation of the immune responses by vaccination emphasizes the need of stimulation of potent cellular immunity based on both Th1 and Th2 cell responses to confer protection against VL.